You are here
Many of the world’s leading interventional cardiologists and cardiovascular professionals will gather in New Orleans May 10-13 for the 40th Annual Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions. The meeting coincides with the 40thanniversary of the first coronary angioplasty, a procedure that revolutionized medicine.
, /PRNewswire/ -- Boston Scientific (NYSE: BSX) has initiated a worldwide study that will evaluate the survival benefit of patients treated with the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System who are aged 65 and older with a history of prior heart attack, diabetes and moderately reduced left ventricular ejection fraction.
iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced the recent publication of two documents in support of extended continuous ambulatory monitoring for arrhythmia detection.
, /PRNewswire/ -- Trends, opportunities and forecast in this market to 2022 by procedure, which includes repair (annuloplasty, valvuloplasty, transcatheter mitral valve repair, and other repairs) and replacement (surgical valves, mechanical heart valves, tissue heart valves, and transcatheter aortic valves), position (aorta, mitral, and other), and region (, , , and the Rest of the World).
Medtronic plc (NYSE: MDT) today announced first enrollments in the STOP Persistent AF clinical trial. The trial will evaluate the safety and effectiveness of a pulmonary vein isolation-only (PVI) strategy for treating patients with persistent atrial fibrillation (AF), using the Arctic Front Advance(TM) Cardiac CryoAblation Catheter. John Harding, M.D., Doylestown Hospital in Doylestown, Penn., treated the first patient enrolled in the trial.
80.0% OF THOSE TREATED FREE FROM REPEAT HEART FAILURE RE-HOSPITALIZATION
Enterprise Imaging for Cardiology is a unified, care-centered and sophisticated imaging platform for cardiovascular professionals.
One heartbeat scans with the industry’s fastest rotation speed in a system that is affordable and accessible in the hospital, chest pain emergency (ED), or point-of-care setting.
SDSU researcher uncovers molecular pathway that protects the heart from damage during a heart attack.
The Cities and Communities with Heart Initiative Nashville brings the community together to stop the #1 killer of women
Two studies presented at the International Conference on Advanced Technologies & Treatments for Diabetes offer additional evidence of how Glytec’s disruptive technologies achieve dramatic and sustained impact on glucose control.
PRO-Kinetic Energy Cobalt Chromium (CoCr) Coronary Stent System from BIOTRONIK gained FDA approval utilizing results from the BIOHELIX-I clinical study. This stent, which has already been used to treat more than 650,000 patients worldwide, is now available in the US.
Mayo Clinic’s Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome and Children’s Hospital of Philadelphia are collaborating to delay and prevent heart failure for hypoplastic left heart syndrome, a rare and complex form of congenital heart disease in which the left side of a child's heart is severely underdeveloped.
Glytec’s solution will enable the 14-hospital health system to achieve best practice, reduce variability and standardize care for patients with diabetes.
Vascular Dynamics, Inc. today announces that the United States Food and Drug Administration (FDA) has approved the company’s application to participate in the Expedited Access Pathway (EAP) program for its MobiusHD® device for the treatment of resistant hypertension.
Geneva Health Solutions (formerly Geneva Healthcare) announced it raised $1.9 million to expand its Cardiac Remote Monitoring Solutions business to cardiology providers to help manage patients with implanted cardiac devices beyond the walls of the practice.
GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Provides Improved Outcomes in Real-World Peripheral Arterial Disease Cases
SCAI Envisions Bright Future with Francesca Dea, Who Brings More Than 20 Years of Experience
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has closed its acquisition of Valtech Cardio Ltd